Gammaa Extracts, Sri Lanka’s first licensed medical cannabis cultivation and export company, proudly made its global debut at ICBC Berlin 2025. Rooted in Ayurvedic tradition and powered by EU-GMP-aligned indoor cultivation, the company showcased its pharmaceutical-grade cannabis strategy to international buyers and partners. With an unrestricted government license and a premium facility under construction, Gammaa Extracts highlighted its low-cost, high-compliance advantages to potential clients from Germany, the UK, and Australia.

​

This milestone event marks the beginning of Gammaa’s global journey as it positions itself to meet the demands of the $444B medical cannabis market. With plans to launch its own “Ceylon Cannabis” line and value-added wellness products, Gammaa Extracts is building a reputation for purity, science, and sustainability from the heart of Sri Lanka to the world.

​

​